Table 3. Guillain-Barré syndrome occurrence during follow-up and during the 6-week (42 days) risk periods following influenza A(H1N1)pdm09 vaccination and infection.
| Exposure | DK | FI | FR | NL | NO | SE | UK | TOTAL | ||||||||
| n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | |
| Cases in study period | 31 | 10.2 | 29 | 9.6 | 41 | 13.5 | 80 | 26.4 | 50 | 16.5 | 32 | 10.6 | 40 | 13.2 | 303 | 100 |
| Follow-up total (mean) in days | 11,286 (364.1) | 6,127 (211.3) | 11,421 (278.6) | 26,322 (329) | 17,845 (356.9) | 11,471 (358.5) | 12,666 (316.7) | 97,138 (320.6) | ||||||||
| Cases exposed to influenza A(H1N1)pdm09 vaccine anytime during follow-up period | 4 | 12.9 | 13 | 44.8 | 5 | 12.2 | 29 | 36.3 | 23 | 46.0 | 22 | 68.8 | 3 | 7.5 | 99 | 32.7 |
| GBS in influenza A(H1N1)pdm09 vaccination risk period | ||||||||||||||||
| 1st dose1) | 2 | 6.5 | 4 | 13.8 | 2 | 4.9 | 10 | 12.5 | 8 | 16.0 | 9 | 28.1 | 1 | 2.5 | 36 | 11.9 |
| 2nd dose1) | 0 | 0.0 | 0 | 0.0 | 2 | 4.9 | 5 | 6.3 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 7 | 2.3 |
| Cases during risk period following seasonal influenza vaccination | 0 | 0 | 1 | 3.4 | 1 | 2.4 | 4 | 5 | 4 | 8 | 0 | 0 | 5 | 12.5 | 15 | 0.05 |
| Cases during risk period following infections (ILI, URTI) risk period | 6 | 19.4 | 6 | 20.7 | 10 | 24.4 | 16 | 20 | 30 | 60.0 | 8 | 25.0 | 3 | 7.5 | 79 | 26.11 |
| ILI1) | 5 | 16.1 | 1 | 3.4 | 2 | 4.9 | 6 | 7.5 | 13 | 26.0 | 1 | 3.1 | 1 | 2.5 | 29 | 9.6 |
| URTI1) | 1 | 3.2 | 5 | 17.2 | 8 | 19.5 | 10 | 12.5 | 17 | 34.0 | 7 | 21.9 | 2 | 5 | 50 | 16.5 |
1)% per number of cases included per country.
Abbreviations: ILI: influenza like illness; URTI: Upper respiratory tract infection; UK: United Kingdom; NL: Netherlands; FR: France; SE: Sweden; FI: Finland, NO: Norway, DK: Denmark.